Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

Table 3

Clinical data from studies with the main multi-target agents in clinical development for the treatment of medullary thyroid cancer.

Author (ref)	Pharmaceutical compound	𝑁	Response rate (%)	Stabilizations (%)	Progression-free survival (months)
Wells Jr. et al. [28]	Vandetanib	231	45	—	Not achieved at 24 months. HR versus placebo = 0.46 𝑃<0.001
Kurzrock et al. [29]	Cabozantinib	37	49	41	Not reported
Lam et al. [30]	Sorafenib	16	6	62	17.9
Capdevila et al. [20]	Sorafenib	34 (15 MTC)	47	40	10.5
Schlumberger et al. [31]	Motesanib	91	2	48	11.2
Carr et al. [23]	Sunitinib	7	37.5	—	Not reported
De Souza et al. [32]	Sunitinib	25	35	57	Not reported